As the popularity of stock picking rises, so do the prospects of long/short equity hedge funds that have helped to drive assets to a struggling hedge fund industry.
A number of launches in the second quarter centered on TMT and biotech sector specialist strategies including firms such as OrbiMed’s New Horizons Fund; biotech fund M28 Capital; Dilation Capital, founded by Lone Pine alum Brian Eizenstat; and the EFF offering from UBS O’Connor.
According to data firm PivotalPath, the majority of hedge fund launches have been either equity diversified or equity sector managers . . .
Continue Reading
Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.
Monthly
$30
A pay-as-you-go plan to get you started
→ Instantly unlock all new and archived articles
→ Daily, weekly and monthly e-mail newsletters
→ Access to the weekly AW Deal Watch by AW Research
Annual
$300
Required for access to AW Research
Get more for less - 20% discount over monthly
→ Everything in Monthly PLUS:
→ Access to articles and data from AW Research
→ AW Annual Investor Compendium – our comprehensive guide to investor activity, with a ranking of the most active investors for the year and profiles of the top global allocators
